Cargando…
Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs
Background: To determine the magnitude of difference between manufacturer-submitted and pan-Canadian Oncology Drug Review (pCODR) calculated incremental cost-effectiveness ratios (ICERs), incremental cost (ΔC), and incremental effectiveness (ΔE); to examine whether there is a significant difference...
Autores principales: | Saluja, Ronak, Jiao, Tina, Koshy, Liza, Cheung, Matthew, Chan, Kelvin K. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924399/ https://www.ncbi.nlm.nih.gov/pubmed/33498460 http://dx.doi.org/10.3390/curroncol28010060 |
Ejemplares similares
-
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
por: Masucci, Lisa, et al.
Publicado: (2017) -
Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
por: Arciero, Vanessa, et al.
Publicado: (2021) -
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
por: Rocchi, Angela, et al.
Publicado: (2015) -
Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study
por: Lexchin, Joel
Publicado: (2019) -
Examining the association between oncology drug clinical benefit and the time to public reimbursement
por: Thomson, Sasha, et al.
Publicado: (2021)